DDInter747 DDInter1658
Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Fludrocortisone {u} (Compound) resembles {v} (Compound) Dexamethasone
Fludrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Testosterone
Fludrocortisone {u} (Compound) binds {v} (Gene) NR3C1
Fludrocortisone {u} (Compound) palliates {v} (Disease) Parkinson's disease
Fludrocortisone {u} (Compound) causes {v} (Side Effect) Hyperglycaemia
Fludrocortisone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Aluminum hydroxide
Fludrocortisone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticlopidine
Fludrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bisacodyl
Fludrocortisone {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Fludrocortisone {u} may lead to a major life threatening interaction when taken with {v} Moxifloxacin
Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Testosterone
Fludrocortisone (Compound) binds NR3C1 (Gene)
Fludrocortisone (Compound) palliates Parkinson's disease (Disease)
Fludrocortisone (Compound) causes Hyperglycaemia (Side Effect)
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Fludrocortisone may lead to a major life threatening interaction when taken with Certolizumab pegol
Fludrocortisone may lead to a major life threatening interaction when taken with Moxifloxacin